KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Liabilities and Shareholders Equity (2020 - 2025)

Ginkgo Bioworks Holdings' Liabilities and Shareholders Equity history spans 6 years, with the latest figure at $1.1 billion for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 18.71% year-over-year to $1.1 billion; the TTM value through Dec 2025 reached $4.8 billion, down 20.31%, while the annual FY2025 figure was $1.1 billion, 18.71% down from the prior year.
  • Liabilities and Shareholders Equity reached $1.1 billion in Q4 2025 per DNA's latest filing, down from $1.2 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.5 billion in Q4 2022 to a low of $1.1 billion in Q4 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $1.8 billion, with a median of $1.7 billion recorded in 2021.
  • Peak YoY movement for Liabilities and Shareholders Equity: surged 206.74% in 2021, then crashed 34.56% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $2.1 billion in 2021, then increased by 22.61% to $2.5 billion in 2022, then plummeted by 34.42% to $1.7 billion in 2023, then dropped by 17.29% to $1.4 billion in 2024, then dropped by 18.71% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for DNA's Liabilities and Shareholders Equity are $1.1 billion (Q4 2025), $1.2 billion (Q3 2025), and $1.2 billion (Q2 2025).